A study led by the University of Barcelona in collaboraiton with the Institute for Bioengineering of Catalonia reveals that the functional assay dynamic BH3 profiling (DBP) can predict whether specific treatments will be effective in non-small cell lung cancer patients. The technique helps determine which therapy will be most effective by testing it directly on living cells, improving personalised therapies.
Researchers from the IBEC and the University of Barcelona (UB) have identified new biomarkers for non-small cell lung cancer, the most common lung cancer. The results, published in the journal Modern Pathology, were obtained thanks to a new technique that allows quantitative analysis of patient samples. It is a pioneering methodology that is cheaper and easier … Read more
One of the great challenges in the fight against cancer is to design new technologies for a personalized treatment for each patient. Depending on the molecular characteristics —DNA mutations for instance— of each tumour, precision medicine aims to make it easier for cancer patients, both adult and paediatric, to receive a personalized treatment that is appropriate to their pathology. But is it possible to know whether or not a patient can benefit from a treatment before starting therapy?
A team of researchers from IBEC and the Faculty of Medicine and Health Sciences at the University of Barcelona have designed a device based on microfluidic physics to predict the efficacy of cancer treatments in a fast and automated way, they have named it microfluidic dynamic BH3 profiling (μDBP). This system brings cancer cells, from … Read more
This advance can help in predicting treatment efficiency thus, avoiding tumor resistance and decreasing undesired secondary effects.